Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped Futility analysis did not support continuation of the trial

Conditions

Platinum Sensitive Ovarian Cancer
Ovarian Cancer

Interventions

BIOLOGICAL: FRα peptide plus Adjuvant (GM-CSF)
DRUG: Adjuvant (GM-CSF) Alone

Sponsor

Marker Therapeutics, Inc.